Financial Times
Dec 16, 2021 - 6 min
All in 1 subscription.
Such trials are expensive; the understanding they produce is worth paying for. Manufacturers can’t make COVID vaccines fast enough. Could fractional doses be the solution to inadequate supplies? Tim Harford talks to experts about whether the concept has an opportunity to save millions of lives.